Screener
Spyre Therapeutics, Inc. SYRE Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001636282-26-000050
| Line item | Three Months Ended March 31, 2026 | 2025 |
|---|---|---|
| General and administrative (2) | 15,230 | 11,944 |
| Gain on sale of in-process research and development asset | (30,000) | — |
| Total operating expenses | 45,641 | 53,567 |
| Loss from operations | (45,641) | (53,567) |
| Other (expense) income: | ||
| Interest income | 6,995 | 6,493 |
| Other (expense) income, net | (30,359) | 2,286 |
| Total other (expense) income | (23,364) | 8,779 |
Item 1. Financial Statements (Unaudited).
FAQ
- What is Spyre Therapeutics, Inc.'s operating income?
- Spyre Therapeutics, Inc. (SYRE) reported operating income of -$45.64M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s operating income changed year-over-year?
- Spyre Therapeutics, Inc.'s operating income increased by 14.8% year-over-year, from -$53.57M to -$45.64M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s operating income?
- Over 4 years (2021 to 2025), Spyre Therapeutics, Inc.'s operating income has grown at a 33.7% compound annual growth rate (CAGR), from -$65.65M to -$209.56M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Spyre Therapeutics, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude